GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Cyclically Adjusted PB Ratio

Myriad Genetics (Myriad Genetics) Cyclically Adjusted PB Ratio : 1.44 (As of Apr. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Cyclically Adjusted PB Ratio?

As of today (2024-04-30), Myriad Genetics's current share price is $19.80. Myriad Genetics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $13.79. Myriad Genetics's Cyclically Adjusted PB Ratio for today is 1.44.

The historical rank and industry rank for Myriad Genetics's Cyclically Adjusted PB Ratio or its related term are showing as below:

MYGN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.97   Med: 2.84   Max: 7.1
Current: 1.32

During the past years, Myriad Genetics's highest Cyclically Adjusted PB Ratio was 7.10. The lowest was 0.97. And the median was 2.84.

MYGN's Cyclically Adjusted PB Ratio is ranked better than
62.88% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96 vs MYGN: 1.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Myriad Genetics's adjusted book value per share data for the three months ended in Dec. 2023 was $8.712. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $13.79 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Myriad Genetics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Myriad Genetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cyclically Adjusted PB Ratio Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.69 1.02 2.18 1.07 1.39

Myriad Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.68 1.67 1.15 1.39

Competitive Comparison of Myriad Genetics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted PB Ratio falls into.



Myriad Genetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Myriad Genetics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=19.80/13.79
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Myriad Genetics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=8.712/129.4194*129.4194
=8.712

Current CPI (Dec. 2023) = 129.4194.

Myriad Genetics Quarterly Data

Book Value per Share CPI Adj_Book
201403 9.693 99.695 12.583
201406 9.783 100.560 12.591
201409 9.757 100.428 12.574
201412 9.707 99.070 12.681
201503 9.553 99.621 12.410
201506 9.610 100.684 12.353
201509 9.901 100.392 12.764
201512 10.765 99.792 13.961
201603 10.940 100.470 14.092
201606 10.826 101.688 13.778
201609 10.753 101.861 13.662
201612 10.762 101.863 13.673
201703 10.987 102.862 13.824
201706 11.234 103.349 14.068
201709 12.585 104.136 15.641
201712 13.173 104.011 16.391
201803 13.576 105.290 16.687
201806 13.684 106.317 16.658
201809 14.755 106.507 17.929
201812 14.538 105.998 17.750
201903 14.738 107.251 17.784
201906 14.815 108.070 17.742
201909 14.442 108.329 17.254
201912 14.459 108.420 17.259
202003 12.983 108.902 15.429
202006 12.292 108.767 14.626
202009 12.092 109.815 14.251
202012 0.000 109.897 0.000
202103 11.411 111.754 13.215
202106 11.615 114.631 13.113
202109 12.153 115.734 13.590
202112 12.098 117.630 13.311
202203 11.876 121.301 12.671
202206 11.754 125.017 12.168
202209 11.330 125.227 11.709
202212 10.909 125.222 11.275
202303 10.248 127.348 10.415
202306 8.977 128.729 9.025
202309 8.328 129.860 8.300
202312 8.712 129.419 8.712

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Myriad Genetics  (NAS:MYGN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Myriad Genetics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (Myriad Genetics) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart officer: Executive VP Human Resources 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury officer: Senior V.P. - Research 320 WAKARA WAY, SALT LAKE CITY UT 84108